Study of HRS-6209 combinations for advanced breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new drug, HRS-6209, combined with different hormone treatments (fulvestrant, letrozole, HRS-8080, or HRS-1358) for people with advanced breast cancer that has spread or cannot be surgically removed and has worsened after previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- Your breast cancer is advanced (has spread or cannot be removed by surgery) and has gotten worse after standard treatments.
- You are either postmenopausal (no menstrual periods for at least 12 months) or before menopause but willing to take a medication to suppress ovarian function.
- You have at least one tumor that can be measured on a scan (like CT or MRI) that isn't in your brain.
- Your overall health is good (you can do most daily activities on your own).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new drug combinations for advanced or metastatic breast cancer. It aims to see if adding HRS-2189, HRS-6209, or HRS-1358 to standard treatments works better. Participants must have tried certain hormone therapies or chemotherapies before.
This study tests a combination of two experimental drugs, HRS-2189 and HRS-5041, for men with advanced prostate cancer that has spread and is no longer responding to standard treatments. The goal is to see if the combination is safe and effective in controlling tumor growth.
This trial tests a new combination of drugs (HRS-6208 with HRS-8080, fulvestrant, or letrozole) for people with advanced or metastatic breast cancer that cannot be removed by surgery. It aims to see if these combinations can help shrink or slow the cancer.
This trial tests a new drug called HRS-6209 combined with other treatments for people with breast cancer that has worsened after previous therapy. It aims to find a more effective way to control the cancer.
This trial tests a combination of new drugs (HRS-8080, SHR-A2009, or others) for people with advanced breast cancer that has stopped responding to previous treatments. The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
This trial tests a new drug, HRS-6209, combined with other treatments for people with hormone receptor-positive, HER2-negative cancer. The goal is to see if the combination is safe and works well.
Hear when a new Advanced Unresectable or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.